Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. Massachusetts General Hospital, Boston, MA, United States

Survival: 17.1 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Boston, MA
Hospital: Massachusetts General Hospital
Journal: Link
Date: 12/2007

Patients: This phase II study involved 147 women with recurrent ovarian cancer. All had received a platinum therapy before entering the study. The median age was 59 years, ranging from 33 to 83.

Treatment: All the women in this study were treated with trabectedin, a chemotherapy drug.

Toxicity: One treatment-related death occurred, due to a combination of dyspnea, pulmonary edema, heart murmur, pleural effusion, pulmonary hypertension, and cardiac failure. Grade 4 neutropenia was reported in one patient. Abnormal laboratory tests were the most common grade 3 adverse event, and neutropenia was the second most common, reported in 10 (7.0%) of patients.

Result: The median overall survival was reported for two different groups and was 17.1 months in the partial-platinum sensitive group, and 11.1 months for the platinum-resistant group. The women were placed into different groups based on whether or not their cancer was platinum sensitive or platinum resistant. The platinum sensitive group was divided into two other groups, partial platinum sensitive and platinum sensitive. Median survival times were not available for the platinum sensitive group.

Support: This study was supported by Johnson and Johnson Pharmaceutical Research & Development, LLC. This company developed trabectedin (Yondelis“, ET-743).

Correspondence: Dr. CN Krasner

E-mail to a Friend Email Physician More Information